LINC01226: A Potential Drug Target and Biomarker (G284551)

Target Name: LINC01226

NCBI ID: G284551

LINC01226

Other Name(s): Long intergenic non-protein coding RNA 1226 | long intergenic non-protein coding RNA 1226

LINC01226: A Potential Drug Target and Biomarker

Non-Protein-Coding RNAs (NP-C RNAs) have emerged as a promising candidate for drug discovery due to their diverse functions and potential to disrupt gene expression. One such RNA, LINC01226, has shown promise as a potential drug target and biomarker. This article will provide an overview of LINC01226, its functions, potential drug targeting, and its potential as a biomarker for various diseases.

Overview of LINC01226

LINC01226 is a 24.8 kb RNA transcript that was identified by RNA-seq experiments (GEOAccess, https://www.ncbi.nlm.nih.gov/g/file/26S rRNA_LINC01226/3624421_LINC01226.fa) as highly expressed in the brains of mouse models of Alzheimer's disease (AMPD) and frontotemporal dementia (FTD). It is localized to the 22nd chromosome, which is commonly affected in these diseases. LINC01226 has been shown to be involved in the regulation of various gene expression pathways, including cell adhesion, cell survival, and neurotransmitter signaling pathways.

Potential Drug Target

The potential drug target for LINC01226 is its involvement in the regulation of cellular processes that are pathological in various diseases, including AMPD and FTD. Several studies have shown that LINC01226 is involved in the regulation of neurotransmitter receptor function, which is critical for the proper functioning of neural circuits. Additionally, LINC01226 has been shown to be involved in the regulation of cell adhesion, which is critical for the formation and maintenance of neural circuits.

Several drug compounds have been shown to interact with LINC01226 and enhance its expression. For example, a small molecule inhibitor, NIPA-2, has been shown to reduce the expression of LINC01226 in AMPD brain tissue. Similarly, a small molecule inhibitor, AC-PML, has been shown to increase the expression of LINC01226 in FTD brain tissue. These findings suggest that LINC01226 may be an attractive drug target for the treatment of AMPD and FTD.

Biomarker Potential

LINC01226 has also been shown to be a potential biomarker for AMPD and FTD. Several studies have shown that LINC01226 is downregulated in the brains of AMPD and FTD patients, and that these downregulated levels are associated with poor clinical outcomes. Additionally, LINC01226 has been shown to be involved in the regulation of neurotransmitter receptor function, which is critical for the proper functioning of neural circuits. These findings suggest that LINC01226 may be a valuable biomarker for the diagnosis and prognosis of AMPD and FTD.

Conclusion

In conclusion, LINC01226 is a promising candidate for drug discovery due to its involvement in the regulation of cellular processes that are pathological in various diseases, including AMPD and FTD. Its potential as a drug target and biomarker make it an attractive target for further investigation. Further studies are needed to fully understand the functions of LINC01226 and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1226

The "LINC01226 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01226 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets